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ABSTRACT 
Urothelial cancer (UC) is the most common malignancy found in the urinary tract. The global annual 
incidence is approximately 430 000 new cases (Sweden: 3 200 new cases). Approximately one in four 
new UC patients being diagnosed has muscle-invasive disease. For curative intent, treatment involving 
surgical removal of the primary tumour remains the gold standard for locally advanced UC. Still, one 
in two patients relapses despite undergoing curative intended surgery or bladder-preserving 
radiotherapy. Platinum-containing regimens have been the standard treatment since the 1980s, despite 
only reaching an overall survival of about 1 year. During the last decade, merely one new chemotherapy 
has been approved for metastatic UC: vinflunine. The primary aim of this thesis was to improve the 
management of advanced and metastatic UC by evaluating experimental treatments and exploring 
predictive and prognostic biomarkers. 
Paper I describes a patient with metastatic UC and with no available standard treatment options after 
failing platinum treatment. The patient received the tyrosine kinas inhibitor sorafenib in second-line for 
almost one year. Immunohistochemistry (IHC) analysis of this patient’s tumour revealed intermediate 
expression of vascular endothelial growth factor receptor 2 (VEGFR2) and high expression of platelet-
derived growth factor receptor β, two key targets of sorafenib. 
In Paper II, the prognostic value of S100A4, S100A6, and VEGFR2, markers of metastasis, 
proliferation and angiogenesis, were analysed by IHC in tumour specimen from 83 UC patients 
following cystectomy of the urinary bladder. Expressions of these proteins were compared with overall 
and disease-free survival. High expression of VEGFR2 and low tumour stage were independently 
correlated with longer survival. No association was found for S100A4 or S100A6 in this cohort.   
The Phase I trial Vinsor (Paper III) was the first clinical study to assess safety of vinflunine plus 
sorafenib in metastatic UC patients, refractory to platinum. Primary endpoint was to define the 
recommended Phase II dose (RPTD). In patients treated with a start dose of vinflunine 280 mg/m2 the 
RPTD of sorafenib was 400 mg. In patients receiving vinflunine 320 mg/m2, the RPTD was not 
determined because of toxicity. The median overall survival was 7.0 months and the overall response 
rate was 41%. 
Predicting early response to treatment is of clinical importance in improving outcome. In Paper IV the 
predictive value of response evaluation with early 18F-FDG PET scans and plasma exosomes were 
analysed in a subset of Vinsor trial patients (Paper III). Results demonstrated that early changes on 18F-
FDG PET predicted survival and RECIST based on subsequent CT scans. Plasma exosomes could be 
isolated and quantified, but analysis revealed no association to treatment response.  
In Paper V, the cytotoxic properties of the peptidase-enhanced alkylating agent melflufen was studied 
in vitro. In UC cell lines melflufen increased cell death compared to melphalan. Aminopeptidases were 
found to be of importance for melflufen efficacy in vitro and high expression of aminopeptidase N 
expression in UC tumour specimens was associated with longer overall survival. 
In summary, the results of this thesis indicate that subsets of UC patients may have a clinical benefit of 
sorafenib and that combined treatment with vinflunine is safe and possibly increases treatment efficacy. 
VEGFR2 appears to have prognostic potential besides being a target for therapy. Early treatment 
assessment of metastatic UC patients with 18F-FDG PET holds predictive potential. Melflufen shows 
antitumoral effects in UC cell lines and could be a future novel chemotherapy against this cancer. 
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1 Introduction urinary tract cancer 
1.1 Definitions 
In this thesis advanced urothelial cancer (UC) is defined as a primary cancer of the urinary tract 
of tumour stage 2 or above (T2+) as described in Classification by the Union Internationale 
Contre le Cancer, Editions VII and VIII 1,2. In Paper II, a minority of cases with UC invading 
the subepithelial connective tissue (T1) were also included. Analysed in the papers are tumours 
with histology of pure or mixed UC, but predominantly of urothelial origin (90% or above).  
1.2 Demography, epidemiology and risk factors 
Urinary tract cancer is globally diagnosed in about half a million patients per annum 3. This 
means that cancer derived from the urinary tract constitutes about 3% of all new cancer cases 
and is the sixth most common cancer for men, nineteenth for women, and eleventh for both 
genders combined worldwide in terms of incidence 3. The incidence of urinary tract cancer 
varies around the world, mainly due to different environmental and lifestyle factors 4. In 
Sweden, 3 156 new cases of urinary tract cancers including the renal pelvis were diagnosed in 
2016 5. The risk of contracting urinary tract cancer varies widely among ethnicity, with 
Caucasians in South and West Europe, Middle East and North America at the top with a 
cumulative 0-74 year life risk of up to 2.5% for men and 0.6% for women. Lowest risks are 
found in and South-Central Asian and West African populations, with approximately a tenth 
of the formers’ cumulative risks 3. Globally, urinary tract cancers account for over 165 000 
deaths per year 3. The high mortality in urinary tract cancers commands a position as number 
thirteen of cancer related causes of death among all cancers worldwide 3. The most common 
direct cause of UC is tobacco smoking 6. Chemicals, mainly arylamines and polycyclic 
aromatic hydrocarbons, are known to cause cancer of the urinary tract 7. Treatment with 
radiotherapy of cancers in the pelvic region and some chemotherapy may increase the risk of 
developing secondary UC 8-10. Age and male gender are other well-known risk factors for UC 
with most patients diagnosed in their seventh or eighth decade 7. Variation in the genes 
encoding N-acetyltransferase 2 and glutathione S-transferase-µ1 and single nucleotide 
polymorphisms have displayed a 10-50% increased risk of bladder cancer 4. Urinary tract 
infection with schistosomiasis is a specifically causality for squamous cell carcinoma 11,12.  
1.3 Classification according to TNM and diagnosis 
UC is staged according to the worldwide accepted tumour, (lymph) node, and metastasis 
(TNM) nomenclature system by Union Internationale Contre le Cancer, with the latest edition 
(VIII) published last year 1. The classification according to tumour infiltration depth was 
proposed in 1946 13. Basically, the TNM system separates non-muscle invasive bladder cancer 
(Ta, Tcis, T1) from muscle invasive bladder cancer (T2-T4). Staging is based on cystoscopy 
(via the urethra), the histopathology diagnosis and radiology (MRI and CT scans with 
functional imaging being optional but often performed) 14. A transurethral resection of the 
bladder is performed to obtain a biopsy of the primary tumour. The proportion of incidence 
between NMIBC and MIBC is about 75-80% versus 20-25% at diagnosis 7. Accurate staging 
is crucial as prognosis and treatment of NMIBC and MIBC differs significantly 14,15. 
 
1.3.1 Histology and WHO grades 
Cells of the urothelial (transitional) epithelium compose the outer cell layer in the urinary tract 
and bladder, and thus are exposed to the metabolites contained in the urine. Deriving from this 
cell layer, UC is the dominant type of cancer arising in the urinary tract, constituting about 90% 
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of all cancers. Much less frequently occurring are squamous cell carcinoma (4%), 
adenocarcinoma (2%), and sarcoma (~1%) 16. The various histological subtypes are treated 
separately as their response to chemotherapy and radiation are different 14. Along with the TNM 
system and histopathological classification, WHO grade adds information about the 
morphological differentiation of the constituting tumour cells 17,18. Classification according to 
tumour grade was originally defined by the WHO in 1973 and updated in 1999, 2004, and 2016 
19. Although the classification criteria varies between the versions, advantages with the updated 
versions have been the focus of debate 20. However, more tumours are classified in the most 
aggressive group with the WHO 2004/2016 grading criteria and less differentiated (high grade 
or grade 3) UC tumours are more likely to have a higher T-stage 19. 
 
1.4 Molecular taxonomy and driving pathways in UC 
Through the characterisation of mutations, gene expression, and epigenetic changes of UC, an 
integrated classification of UC is arising 21-23. Thus, protein expression analyses of UC tumours 
from a group of 237 patients with muscle-invasive UC identified 20 proteins, collectively 
associated with significantly different molecular pathology and survival 23. The proteins 
identified included cyclin B1, D1, E1, cyclin dependent kinase inhibitor 2A, desmocollin 2/3, 
E2F transcription factor, EGFR, ERBB2, FGFR3, E-, N- and P-cadherin, MKI67, TP63, RB1, 
uroplakin 3, cytokeratin 5, 6, 14, and 20 23. By combining these factors, three molecular 
subtypes of UC have emerged: urobasal, genomically unstable, and squamous cell carcinoma-
like 23. In a similar approach, 131 UC tumours had their mRNA, miRNA, and protein 
expressions analysed 24. Mutations, copy number alterations, and RNA expression changes 
associated with UC included the PI3K-AKT and RTK-MAPK signalling pathways, amounting 
to 42-45% of the analysed cases. The most common alteration identified in each pathway was 
activating point mutations in PI3KCA (17%) and FGFR3 (17%). The authors identified four 
distinct subtypes of UC 24. Two additional groups have performed discovery analyses on the 
molecular level for pathophysiological alterations in UC 21,22. Pooled data from the published 
data sets have been compiled and analysed 25. From this extensive analysis it was concluded 
that UC tumours can be classified into two major types: urothelial and squamous-like 
differentiation with extracellular matrix and immune related gene alterations. The smaller 
cohort (“basal” or squamous cell carcinoma-like) showed up-regulation of most of the 
previously identified 20 genes, whereas the larger cohort (luminal or urobasal A and 
genomically unstable) displayed an inverse pattern 25. It is still unclear how the molecular 
alterations correspond to therapy outcome. The collective data has identified the most active 
pathways in UC development: the MAPK/ERK (RAS-RAF-MEK-ERK) and PI3K-AKT-
mTOR signalling transduction routes 26.  
 
1.5 Treatments  
Initially cancer of the urothelial tract was solely treated by surgeons. With the advances in 
clinical oncology, megavoltage radiotherapy emerged as a treatment option in the 1950s 27. 
Among the first systemic chemotherapeutic agents to be evaluated in UC were cisplatin and 
the anthracycline doxorubicin, both of which were tested in the late 1960s and early 1970s 28,29. 
Chemotherapy combinations which included cisplatin were gradually introduced from the late 
1970s 30,31. Despite the increased incidence and latest pharmacologic developments including 
biologics, treatment options in locally advanced and metastatic UC remain limited 32,33. 
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1.5.1 Chemotherapies 
Neoadjuvant Setting 
In 1985 the first patient in the Nordic Cystectomy Trial I was randomised between two cycles 
of cisplatin and doxorubicin followed by low dose radiotherapy and cystectomy or radiotherapy 
and cystectomy alone 34. This trial and the successor reported improved survival with NACT 
34-36. Subsequent trials have confirmed and established NACT as the standard protocol in 
advanced UC with curative intention 37. This regimen typically consists of three to four courses 
of gemcitabine and cisplatin (GC) or methotrexate, vinblastine, doxorubicin and cisplatin 
(MVAC) followed by cystectomy. The purposes of NACT are dual: to shrink the primary 
tumour and to treat micro-metastases. One meta-analysis has confirmed a 5 percentage-point 
gain in OS 37. The PD1 inhibitor pembrolizumab and the PDL1 inhibitor atezolizumab were 
evaluated before radical cystectomy in separate single armed Phase II studies 38,39. In the future, 
this could hopefully be improved with implementing a more precise strategy for UC patients 
based on biomarkers.  
 
Adjuvant Setting 
Several clinical trials have evaluated the effect of adjuvant chemotherapy in UC 40. The results 
of these trials have not produced solid evidence for adjuvant chemotherapy in UC 41. Currently, 
this treatment strategy is not recommended in clinical routine but only to selected patients who 
have not for any reason received neoadjuvant therapy and present with a histopathology of 
pT3/pT4 and/or pN+ 14. 
 
Palliative setting – first-line 
In the 1970s, single treatment with cisplatin and doxorubicin produced response rates of 20% 
to 35% in patients with advanced UC 31,42. Further development of chemotherapy combinations 
eventually determined MVAC as the regime with the highest response rate at 55% 30. This 
regimen has been improved and renamed HD-MVAC by optimising the doses and schedule 
besides minimising neutropenia by adding GCSF, consequently lifting the response rate to 62% 
43. However, significantly lower frequency of toxicity favours GC as first-line treatment in 
advanced UC 44. The triplet GCP was found to improve the response rate to 56%, but without 
significant improvement in OS in the intention-to-treat population 45. For cisplatin fit patients, 
the median OS is limited to 14-15 months 44. However, 30-50% of UC patients are unfit to 
receive cisplatin due to renal dysfunction 46. Patients with renal impairment, poor performance 
status or co-morbidity to whom cisplatin cannot be given, carboplatin-based combination 
regimens or gemcitabine monotherapy offers an alternative treatment option in addition to 
immunotherapies (see section 1.5.3) 47. For cisplatin unfit patients, the median OS is 8-9 
months with conventional chemotherapy 47. 
 
Palliative setting – second-line 
The short survival on first-line chemotherapy in UC clearly illustrates the need for further 
treatment options. Numerous drugs have been tested in second-line as monotherapy or as 
doublets 33. Two of the most promising drugs tested were nab-paclitaxel and pemetrexed. Two 
small Phase II trials of these drugs claimed median OS of 9.6 and 10.8 months, respectively 
48,49. Later, larger trials in UC failed to confirm the effect of pemetrexed, resulting in an 
objective response rate of only 5% and median PFS of 2.4 months 50. The vinca alkaloid 
vinflunine was initially tested in two Phase II trials, describing median OS of 6.6-8.2 months, 
 4 
respectively 51,52. In the Phase III Registration trial, vinflunine was concluded to add a median 
OS of 2.3 months in second-line UC treatment following platinum failure, compared with BSC 
only 53. Presently, vinflunine is the only approved chemotherapy after cisplatin failure in UC 
within the European Union 14. Nevertheless, multiple trials are investigating other drugs and 
also vinflunine treatment combinations 54. Studies in mUC of vinflunine doublet combinations 
have resulted in unacceptable toxicity in second-line (pemetrexed, pazopanib) but promising 
ORR and OS in first-line (gemcitabine, carboplatin) 55-57. 
1.5.2 The peptidase-enhanced alkylating agent melflufen  
In the current thesis the novel peptidase enhanced alkylating agent melflufen (L-melphalanyl-
L-p-fluorophenylalanine ethyl ester hydrochloride) has been explored (Paper V). Melflufen is 
a Swedish invention developed at Uppsala University and Karolinska Institutet 58-61. Melflufen 
is a dipeptide of para-fluoro-L-phenylalanine and the active moiety melphalan and allows for 
rapid loading of the drug inside cells (Figure 8). Subsequently aminopeptidases cleave the 
peptide bond, releasing high amount of melphalan which alkylates DNA 62. This increased 
amount of DNA damage causes increased cell death in tumour cells 30,58-69. A role for 
aminopeptidases in the conversion of melflufen to free melphalan has been demonstrated using 
bestatin and siRNA against aminopeptidase N (ANPEP) 70, 64,69. Melflufen (Ygalo®) is 
currently in clinical evaluation by Oncopeptides AB for treatment of multiple myeloma (MM)  
in several Phase II/III clinical trials (www.oncopeptides.se, 71). A phase I/II trial of melflufen 
in MM has been completed and demonstrated that melflufen was well tolerated and had clinical 
efficacy in late stage MM patients 62. A “first-in-man” Phase I/II clinical trial of melflufen in 
patients with solid tumours has also been carried out at Karolinska Institutet and Uppsala 
University. Results have demonstrated tolerability, yet with (expected) toxicity related to bone 
marrow cells 72.  
Melflufen is converted to free melphalan by aminopeptidases. Aminopeptidases in general and 
ANPEP in particular, have been demonstrated to have increased expression in tumours of 
different origin, e.g. breast, lung, colorectal, and pancreatic cancer, and have in some tumour 
types been linked to poor prognosis or a metastatic phenotype 70,73. In UC specimens, ANPEP 
has been described as localised to stromal cells 74. Similarly to other malignancies, tumour 
stroma expression of ANPEP has also been described 70,75. ANPEP has been explored for 
tumour therapy purposes 73. The role of ANPEP in PET imaging using either labelled peptides, 
small molecules or affinity probes has been applied in a mouse model70. Thus, ANPEP is an 
interesting biomarker to further explore in UC specimens which was carried out in the current 
study. 
 
1.5.3 Immunotherapies 
During the past two years, immuno-oncology-based therapies including pembrolizumab, 
nivolumab, atezolizumab, durvalumab, and avelumab represent a major breakthrough for the 
treatment of metastatic UC patients within the post-platinum setting 76-80. These therapies have 
reported an OS of up to 10.3 months and an ORR of up to 26% in second-line or beyond with 
durable responses 76,81. For patients who are unfit to cisplatin-based combination 
chemotherapy, pembrolizumab and atezolizumab have been approved as treatment options, 
alongside with carboplatin-based regimens, for patients with high PDL1 expression82-85. 
Nonetheless, most metastatic UC patients do not respond to immunotherapy, and these patients 
need potent subsequent treatment, supporting further development of combination regimens of 
chemotherapy and other anticancer treatments.  
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1.5.4 Therapeutic antibodies 
Several therapeutic antibodies have been examined in UC with different success. The 
monoclonal antibody bevacizumab, which blocks VEGFA, has been tested in addition to first-
line palliative chemotherapy 86,87. Addition of bevacizumab increased ORR but was also 
associated with increased toxicity. Last year, the RANGE study in second-line post-platinum 
in metastatic UC reported ORR of 24.5% with docetaxel and the monoclonal antibody 
ramucirumab targeting VEGFR2 88. Patients receiving ramucirumab and docetaxel had about 
1½ months longer PFS than in patients receiving docetaxel plus placebo. HER2 is a confirmed 
negative prognostic factor for survival in breast, ovarian and gastric cancers 89-92. In a Phase II 
trial on trastuzumab it was found that only 13.3% of UC patients overexpressed HER2 and no 
significant improvement in OS was confirmed when trastuzumab was added to GC in the 
HER2 group as first-line palliative treatment 93. An earlier Phase II trial with trastuzumab in 
addition to paclitaxel, carboplatin, and gemcitabine found 49% of UC patients to express HER2 
and 57% of the HER2 positive patients responded to the treatment with a median OS of 14.1 
months 94. 
 
1.5.5 The tyrosine kinase inhibitor sorafenib 
 
Sorafenib, a TKI, initially approved for renal cell carcinoma, inhibits phosphorylation of key 
target proteins of the RAF-MEK-ERK signalling pathway including Raf-1, B-Raf, ERK1/2, 
PDGFRβ, VEGFR2/3, Flt3, and c-KIT.95,96 The indication was subsequently extended to 
include hepatocellular carcinoma and thyroid cancer supported by phase 3 trials demonstrating 
improvement in survival.97,98 Altered signalling in angiogenic pathways of UC tumours 
supported the hypothesis of sorafenib activity in UC, as well as individual cases with 
favourable outcome 99,100. A Phase II first-line study in metastatic UC analysed the addition of 
sorafenib to GC 101. The study reported an ORR of 52.5% versus 47% with standard treatment, 
and an OS of 11.3 months compared with 10.6 months. A single-armed neoadjuvant study 
combining GC with sorafenib in muscle invasive UC reached a pT0 rate of 43.5% with 26.1% 
grade 4 toxicity 102. A phase 2 trial evaluated first-line sorafenib monotherapy in 17 patients 
with mUC 103. The study reported a median OS of 5.9 months, but no responses were reported. 
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Figure 1. Anti-tumour effects of sorafenib. The multikinase inhibitor sorafenib directly targets the 
tumour expressed growth factor receptors c-KIT and RET, by inhibiting their autophoshorylation status 
(I). This influences their down stream targets, e.g. PI3K/AKT and SRC, resulting in partially inhibition 
of proliferation through transcriptional regulation (II). Sorafenib blocks RAF-1, B-RAF, MEK1/2 
phosphorylation in cells and indirectly causes inhibition of ERK-mediated proliferative networks (III). 
Sorafenib alleviates blockers of mitochondria-mediated apoptotic signalling, e.g. Mcl-1 and Bcl-2, and 
enables pro-apoptotic signalling proteins, e.g. Bad, to work, resulting in increased cytochrome c release 
and promotion of apoptosis (IV). Sorafenib may cause a direct blockade of VEGFR2 
autophosphorylation in vascular or lymphatic endothelial cells (V) and impair downstream Raf-
1/MEK/ERK signaling cascade (VI). This reults in impairment of vascular endothelial cell proliferation, 
migration, and tubule formation thereby inhibiting angiogensis within the tumour (VII). 
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1.5.6 Radiotherapy 
Radiotherapy in UC has been a long-standing modality for selected indications, mainly for 
curative treatment of fragile and older patients with muscle-invasive disease and for palliation. 
For a suitable subset of UC patients with organ-confined disease (T2-3N0M0) combining 
radiotherapy with NACT or concomitant chemotherapy upfront produces response rates of 
88% and a three-year disease-specific survival rate of 82% 104,105. This approach offers the 
advantage of bladder preservation. Attempts to modify the dose regime in radiotherapy 
treatment of organ-confined MIBC (T2-4N0M0) have been undertaken 106. The trend shows 
non-inferiority results with hypofractionated courses from conventional courses of 64 Gy/fx 2 
Gy 107. Adding chemotherapy to radiotherapy has been shown to improve efficacy with local 
disease-free rates of 67% without significant increase in side-effects 108. 
 
1.5.7 Surgery 
As early as in the 17th century, a very perceptive and enquiring surgeon named Fabrice de 
Hilden described a protruding mass in the bladder in one of his patients 109. Modern surgical 
interventions are considered to have been developed in the late 19th century 110. In the last 
century surgical techniques made substantial progress 111,112. Localised non-muscle invasive 
UC is since long time ago treated with transurethral resection, alone or in combination with 
intravesical instillation of either bacillus Calmette–Guérin vaccine, epirubicin, or mitomycin, 
depending on risk of progression 113-115. For low and intermediate grade tumours with medium 
and high risk of relapse or progression a single dose of mitomycin is instilled into the urinary 
bladder after resection 116. For high grade tumours, 6 weekly induction therapies with bacillus 
Calmette–Guérin promoting an immune response and delaying relapse is recommended based 
on two meta-analyses 117,118. For organ-confined muscle invasive UC, radical or in selective 
cases partial cystectomy including pelvic lymph node dissection is recommended as first-line 
treatment 14. Following cystectomy approximately 50% of UC patients will relapse 119,120. All 
relapsing patients should be considered for systemic treatment with the aim of prolonging 
overall survival and improving quality of life.  
 
1.6 Evaluation of systemic treatment in advanced and metastatic UC 
1.6.1 CT 
The most utilised imaging system in UC is CT scans 121. The CT technology provides relatively 
accurate and fast diagnostic radiology assessment of a patient’s local or global tumour status 
121. Evaluation of systemic treatment is therefore routinely done with CT 14. The anatomic 
assessment is based on the RECIST version 1.1 definitions 122-124. However, CT has technical 
shortcomings, where other diagnostic techniques have evolved 125.  
1.6.2 PET 
A meta-analysis including six studies of PET in urinary bladder cancer concluded that 18F-FDG 
PET improves diagnostic imaging accuracy of metastasis over CT and MRI 126.  Hence, 
imaging by PET has become more frequently used in bladder cancer and reports of 18F-FDG 
PET CT restaging in up to 22% of MIBC patients leading to a change of therapy in 14% 127. 
As most 18F-FDG PET CT scanned UC tumours were upstaged, the two most common changes 
in therapy were adding NACT or converting the treatment indication from curative to palliative 
127,128. Apart from 18F-FDG, other radiolabelled tracers evaluated in bladder cancer include 11C-
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acetate and 11C-choline 129. However, a meta-analysis found these tracers to have low detection 
rate of lymph node metastases 129.  
 
 
1.7 Potential clinical and molecular biomarkers 
Non-invasive ways to monitor treatment responses are needed, to optimise and individualise 
treatment.  
 
1.7.1 Prognostic clinical parameters in metastatic disease  
A few prognostic clinical parameters in UC have been identified 130,131. Karnofsky performance 
status scale of less than 80% and lung, liver, or bone metastasis were found to be independent 
prognostic factors affecting OS in UC patients receiving MVAC 130. Presence of 0, 1, or 2 
factors resulted in median OS of 33, 13.4, and 9.3 months, respectively 130. Performance status 
of 1 or higher, anaemia (Hb <10 g/dL), and presence of liver metastasis have been identified 
as negative prognostic factors in metastatic UC upon failure of platinum containing 
chemotherapy 131. Another study also identified the presence of visceral metastases and low 
albumin levels as additional negative prognostic factors 132. In second-line an additional 
negative prognostic factor has been identified in time from prior chemotherapy 133.  
 
 
1.7.2 Development of molecular biomarkers  
Yet, molecular biomarkers in UC are not utilised in clinical routine. Pioneering research in this 
field has lately been undertaken by several laboratories 21-24. An interesting finding was a p53-
like UC subtype, in which the p53 expression could predict between chemoresponsive and 
chemoresistant MIBC tumours 21 (see section 1.4). In the neoadjuvant setting, a report on 
molecular biomarkers in NACT treated MIBC patients (n=37) found that 
Glycerophosphodiester Phosphodiesterase Domain Containing 3 (GDPD3) and Sprouty-
Related, EVH1 Domain-containing Protein 1 (SPRED1) gene expressions were predictive 
markers for GC treatment 134. GDPD3 is involved in the metabolism of glycerol and SPRED1 
down regulates the formation of lymphatic vessels via VEGFC and VEGFR3 by blocking ERK 
activation 135. In the neoadjuvant setting, gene expression profiles of UC tumours have 
provided predictive data on response to MVAC treatment 136.  
 
1.7.3 Liquid biopsy derived exosomes  
The excretion of membrane-surrounded extracellular vesicles (EVs), e.g. microvesicles and 
exosomes, from different cells in the body into plasma has for cancer research generated a 
source of biomarkers 137-140. Of particular interest in tumour biomarker perspectives are 
exosomes, vesicles <150 nm, which are generated from the cellular endosome system and in 
contrast to other EVs released by living tumour cells139. Another feature that makes exosomes 
attractive as a source of biomarkers is their content of protein, RNA, and to some extent DNA, 
which is thought to reflect the cell of origin 141,138,142. Tumour derived exosomes (TDEs) are 
reported to act as communicators between the tumour and its surrounding tumour 
microenvironment, e.g. tumour stroma and infiltrating immune cells thereby regulating several 
hallmarks of tumours, including immune response and metastatic potential.
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2 Aims of the thesis 
 
The overall aim of this thesis was to improve treatment and treatment evaluation methods in 
advanced and metastatic UC. Thus, focus was on evaluating novel treatments and treatment 
combinations with the long-term intention of decreasing disease burden and improving 
survival for these UC patients. Another focus of this thesis was to analyse potentially 
predictive and prognostic biomarkers to improve personalised treatment in advanced and 
metastatic UC. The specific aim for each paper was to: 
 
• characterise a patient with metastatic UC with unexpected clinical benefit in 
response to treatment with sorafenib (Paper I).   
 
• analyse the protein expression levels of VEGFR2, S100A4, and S100A6 in 
tumour specimen of cystectomy treated UC patients and correlate expression levels 
with survival outcome to identify possible prognostic biomarkers (Paper II). 
 
• evaluate safety and to define the recommended Phase II dose of combined 
vinflunine and sorafenib second-line treatment in advanced and metastatic UC 
(Paper III). 
 
• explore the potentially predictive value of early treatment response markers with 
18F-FDG PET and plasma exosome analyses in advanced or metastatic UC patients 
treated with vinflunine plus sorafenib (Paper IV).   
 
• evaluate the antitumoral effects, pharmacodynamic mechanism and potentiating 
ability of the novel peptidase activated alkylating agent melflufen in UC cell lines in 
vitro and analyse an enhancing peptidase, ANPEP, in UC tumour specimen and 
compare with survival outcome (Paper V). 
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3 Patients, material, and methods 
 
3.1 Patient cohorts and analyses  
The analysed UC patients were included at the Dept of Oncology, Karolinska University 
Hospital, Solna, Sweden (Paper I-V), Dept of Oncology, Rigshospitalet, University Hospitals 
of Copenhagen, Denmark (Paper III), and Dept of Oncology, Aarhus University Hospital, 
Aarhus, Denmark (Paper III). Two principal cohorts were used in the present thesis. In Paper 
II and Paper V, 83 patients with urothelial carcinoma or mixed histology with dominance of 
urothelial carcinoma, and who had undergone cystectomy were evaluated for putative 
prognostic immunohistochemical protein markers. Further, a second cohort of 22 patients with 
post-platinum metastatic disease with pure urothelial histology, was studied in Paper III, in 
the prospective dose-finding Phase I trial Vinsor, evaluating a novel treatment combination of 
vinflunine plus sorafenib. Thirteen of these patients also consented to participate in the 
explorative add-on study presented in Paper IV, which evaluated the putative predictive value 
of 18F-FDG PET and exosomes as methods for early treatment evaluation. All preclinical and 
clinical studies were undertaken with approved ethical and regulatory permissions.  
3.2 Immunohistochemistry 
Immunohistochemistry (IHC) is an established method for examining protein expression in situ 
in tumour specimen using antibodies and was applied in Paper I, II and V. Prepared FFPE of 
UC tumour specimens were retrieved from the Biobank at Karolinska University Hospital in 
Solna. Primary antibodies used for the IHC were: anti-PDGFR-β (Paper I), anti-VEGFR2 
(Paper I, Paper II), anti-S100A4 (Paper II), anti-S100 A6 (Paper III) and anti-ANPEP 
(Paper V). All antibodies apart from the anti-ANPEP were obtained from commercially 
sources and had previously been used for IHC on tumour specimens. The ANPEP antibody 
was generated in-house by immunising rabbits with a peptide towards ANPEP followed by 
isolation of monospecific IgG from rabbit serum (Paper V). All primary antibodies were tested 
in preparatory experiments to establish proper concentrations to be applied on the UC 
specimen. To visualise primary antibody binding anti-rabbit secondary antibody conjugated 
with biotin (Vector Labs) was applied followed by avidin-biotin peroxidase complex staining 
and 3,3-diaminobenzidine (DAB). DAB is in this reaction oxidized and a brown precipitate 
corresponding to primary antibody binding is generated in the specimen which can be 
visualised by light microscopy. The staining by the different primary antibodies were evaluated 
in a representative area of the tumour specimen as judged by the pathologists. On each slide, 
the number of stained cells (classified into score) and their staining intensity (negative (0), 
weak (1), moderate (2), and strong (3)) was evaluated by pathologists blinded to the patient 
characteristics. The product of score and intensity was used to dichotomise the patients into 
groups; low and high expression of the proteins studied (VEGFR2, S100A4, S100A6, and 
ANPEP) with subsequent analyses of relation to survival.  
3.3 Phase I clinical trial Vinsor 
In Paper III, a multicentre Phase I trial was set up to evaluate safety of sorafenib in addition 
to standard second-line therapy: vinflunine in advanced or metastatic UC. The trial was 
conducted at three sites within the framework of NUCOG and coordinated from the Dept of 
Oncology, Karolinska University Hospital, Solna.   
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3.3.1 Study design 
The study implemented a classic stepwise dose-escalation design with 3+3 patients at each 
dose level with the primary endpoint to define the RPTD by evaluating safety. This practise is 
well described in early clinical trials and is a compromise to minimise the number of subjects 
exposed to unknown toxicity while keeping a steady flow of patients to find the maximum 
tolerated dose (MTD) of the experimental treatment combination. At each dose-step, a 
minimum of two and maximum of six patients will be treated. Special surveillance including 
overnight stay for the first patient treated within the Vinsor trial was carried out. Subsequently 
recruited patients were all closely monitored during the first two treatment cycles including 
weekly research nurse appointments. All patients were seen by a physician prior to starting 
every new treatment cycle. The MTD is used to define the RPTD which is one dose-step below 
the MTD. If at the highest planned dose level for sorafenib, no DLT is observed, then the RPTD 
will equal the MTD. 
3.3.2 Dose-limiting toxicity 
DLT was in Paper III defined as either a haematologic or non-haematologic toxicity. 
Haematologic toxicity (according to CTCAE 4.0): 
i/ grade ≥4 neutropenia (absolute neutrophil count <0.5 x 109 for ≥ 7 days or <0.1 x 109 for 
≥3 days), or  
ii/ febrile neutropenia of grade ≥3 (absolute neutrophil count <1.0 x 109 and temperature ≥ 
38.5˚C), or 
iii/ platelet count <25 x 109/L or thrombocytopenia with bleeding or requiring platelet 
transfusion. 
 
Non-haematologic toxicity was defined as a DLT (based on CTCAE 4.0) if: 
liver toxicity (ALAT or ASAT) of grade ≥3 for >7 days, or  
any other grade ≥3 major organ toxicity. 
 
3.3.3 Primary and secondary endpoints 
The primary endpoint of the Phase I study Vinsor presented in Paper III, was to define the 
RPTD by analysing safety parameters from treatment cycles 1 and 2. The secondary endpoints 
included data on safety parameters from all treatment cycles, duration of overall and 
progression free survival, overall response rate (including disease control rate and tumour 
response) measured according to RECIST 1.1 at every second treatment cycle. Additionally, 
readouts of early 18F-FDG-PET CT in relation to conventional RECIST 1.1 assessments were 
collected for explorative analysis presented in Paper IV. 
3.4 CT and PET Imaging  
In Paper I, III, and IV, CT scans at pre-scheduled time points were conducted to assess 
treatment response. The scans followed clinical routine protocols and included intravenous 
contrast for optimal visualisation of tumours. Radiologic assessment on anatomical tumour 
response was undertaken according to RECIST 1.1 122-124. In Paper IV, patients underwent 
PET CT scans after receiving glucose labelled with the radioisotope 18F. This procedure was 
repeated after 3 weeks treatment. Examination of metabolic 18F-FDG response was done 
according to adapted PERCIST 1.0 143. Raw data was extracted with the Volume Viewer for 
Advantage Workstation (GE Medical Systems, Milwaukee, WI, USA) and separately analysed 
to examine different threshold SUVmax and SUVpeak levels for explorative early response 
evaluation.   
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Figure 2. Experimental set up analyses of the Vinsor trial. (I). In the Phase I Vinsor trial (EudraCT 
Number: 2011-004289-14, NCT01844947) 22 patients with mUC were included, evaluated for safety 
and for establishing recommended Phase II dose of combined vinflunine and sorafenib second-line 
treatment (Paper III). (II). A subset of the Vinsor mUC patients (n=13) were analysed to explore the 
potentially predictive value of early treatment response markers with 18F-FDG PET (Paper IV). 
Tumour and liquid biopsies (blood, plasma and urine) were taken at baseline, at day 8 and day 21 after 
treatment (Paper IV). (III). From plasma samples of some of the mUC patients (n=5) EVs were isolated 
at baseline, day 8 and day 21 using qEVoriginal size exclusion columns. EVs from fraction 8 were used 
to reveal amount EVs/ml and their using Nanoparticle Tracking Analysis. Data was analysed in relation 
to OS of the patients. Fraction 6-10 from the qEVoriginal size exclusion columns were applied in 
western blotting (WB) to verify expression of exosome markers (CD9 and CD63). 
 
3.5 Exosome isolation and analyses  
In Paper IV EVs were isolated from plasma from a subset of patients enrolled in the Phase I 
study Vinsor (Figure 2). For isolation of EVs from plasma either of two principal methods are 
used; ultracentrifugation and size exclusion chromatography both which separate out EVs of 
different sizes 140. In Paper IV qEVoriginal size exclusion chromatography columns (Izon, 
Oxford, UK) was applied for isolation of EVs using 600 µL of filtered plasma. For the results 
presented in Paper IV, a fraction of 500 µL of eluting PBS was manually collected and 
analysed for EVs size and amount using Nanoparticle Tracking analyses (NTA) with a NS300 
instrument (NanoSight, Malvern Panalytical, Malvern, UK). In NTA the sample to be analysed 
is put in a chamber through which a laser beam is passed. The particles in the sample will 
scatter light and this captured live on a 20x magnification microscope using a video camera. 
The particle size of the sample is presented in nm with a histogram showing the distribution 
into different sizes including exosomes (≤150 nm) and larger EVs 139,140. To verify the presence 
of exosomes in the EV samples western blotting was carried in which two EV markers, CD9 
and CD63, were probed for. The software of NTA can be used to calculate the number of 
particles in a fixed sample volume based on the particle movement and in Paper IV this 
generated EVs/ml which was corrected for extracted plasma volume to give EVs/ml plasma. 
The difference in EVs/ml of plasma was in Paper IV subsequently studied between the patients 
and during the treatment course. 
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3.6 Preclinical characterisation of melflufen response in UC cell lines in vitro 
In Paper V melflufen and melphalan was evaluated in UC cell lines in vitro with respect to 
cell cytotoxicity, cellular accumulation/metabolism, induction of apoptosis, and capacity to 
alter the phosphorylation status of tumour growth regulating kinases (Figure 8). A brief 
summary of the methods is described below.  
3.6.1 Cell lines and cell culture 
In Paper V established human UC cell lines were used to study melflufen action mechanisms. 
The cell lines studied, which all were from obtained from American Type Culture Collection® 
(Manassas, VA, USA) were J82 (HTB-1™), TCC-SUP (HTB-5™), 5637 (HTB-9™), and RT4 
(HTB-2™). J82 and TCC-SUP are both transitional cell carcinomas 144,145. 5637 is a grade II 
carcinoma while RT4 is a transitional cell papilloma 145,146. These cell lines have for long been 
used in experimental oncology research and have recently been profiled for mutations on a 
global scale with results presented in the Cell Strainer database: 
http://depmap.org/portal/cell_line. Prior to publication all cell lines were authenticated using 
Short-tandem repeats (STR) analyses by polymerase chain reaction (PCR). Cells were 
maintained in RPMI-1640 cell medium (Invitrogen, Carlsbad, CA, USA) and cultured as 
monolayer for the experiments.  
3.6.2 Analysis of cell cytotoxicity 
To assess the capacity of melflufen to induce cell death in UC cells, two different assays 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium salt bromide (MTT) assay and 
fluorometric micro culture cytotoxicity assay (FMCA) were used. For both assays UC cells 
were plated in 96-well plates at a density allowing proliferation during treatment with melflufen 
or melphalan (1h pulse or 72h of continuous treatment). MTT or FMCA assay was carried out 
at 72h after adding drug. In the MTT assay, cell viability is assessed by adding MTT solution 
which if cells are alive and have functional mitochondria, will be metabolised to formazan 
crystals that are solubilised and resulting absorbance measured in a microplate reader 147. In 
the FMCA assay cell viability is monitored by addition of a fluorescein diacetate (FDA) probe 
which in viable cells with intact plasma membrane will be hydrolysed to fluorescein that is 
quantified by a microplate reader 148. In both assays the measured absorbance is proportional 
to the number of viable cells and was used in Paper V.  
 
3.6.3 Intracellular accumulation and metabolism of melflufen 
Melflufen treatment has in other tumour cell types been demonstrated to result in rapid 
intracellular loading of melphalan which subsequently causes DNA damages (see section 
1.5.2). Bestatin-inhibited aminopeptidases, including ANPEP, are involved in this 
biotransformation of melflufen to melphalan and esterases may also act on melflufen in tumour 
cells generating a deesterified form of melflufen 64,69. In Paper V the biotransformation of 
melflufen to melphalan or deesterified form in UC cells were analysed. UC cells in suspension 
were exposed to melflufen or melphalan either alone or in presence of bestatin for different 
times (0-60 minutes). A sample was taken out and the biotransformation stopped by adding 
cold PBS. Proteins in the samples were precipitated by acetonitrile:ethanol and resulting 
supernatants taken for analyses of melflufen, melphalan or deesterified melflufen by HPLC-
MS/MS. The MS spectra of the compounds was analysed, and drug concentration estimated 
using standards. To visualise the difference in melphalan amount after melflufen or melphalan 
treatment of the UC cells, the area under the curve over the entire treatment period was 
calculated from different biological replicates. 
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3.6.4 Profiling of apoptotic signalling 
Induction of apoptosis is one way by which tumour cells may respond to chemotherapy. In 
Paper V apoptotic signalling after melflufen, melphalan and in some cases cisplatin treatment 
were analysed in UC cells by assessing apoptotic morphology of cell nuclei, cleavage of 
procaspase-9 into active caspase-9, cleavage of PARP1 as a measure for general caspase 
activity and conformational change/activation of the Bcl-2 proapoptotic proteins Bak or Bax 
(Figure 8).  
Assessment of apoptotic morphology of cell nuclei 
Induction of apoptotic morphology of cell nuclei in response to melflufen or melphalan in UC 
cells were studied by staining fixed cells with 4',6-Diamidine-2'-phenylindole dihydrochloride 
solution (DAPI). DAPI is a dye that binds certain regions in DNA and which can be monitored 
by fluorescence microscopy. In healthy cells the DNA in cell nuclei is homogenously stained 
by DAPI but as apoptosis starts the chromatin structure is altered and therefore DAPI will give 
another staining pattern of DNA with regions of bright staining (seen as dots).  
Cleavage of procaspase-9 and PARP1 by western blotting 
The apoptotic cascade involves activation of proteases so-called caspases which cleaves both 
signalling-and structural proteins which give rise to an apoptotic phenotype 149-152. In Paper V, 
cleavage of procaspase-9 as well as PARP-1 was examined by western blotting in UC cells 
after melflufen- or melphalan treatment. An apoptotic response was mounted as disappearance 
of full-length procaspase-9 or PARP1 and appearance of shorter cleaved forms of either 
protein.  
Analyses of proapoptotic conformation of Bax and Bax 
Treatment of tumour cells with DNA damaging agents triggers apoptotic signalling via the 
mitochondria resulting in cytochrome release and activation of caspases 152-154. It has been 
shown that DNA damages may trigger Bak and Bax to adopt a proapoptotic conformation 
allowing them to promote cytochrome c release from mitochondria 153,154. In Paper V the pro-
apoptotic conformational change of Bak and Bax after melflufen-, melphalan- or cisplatin 
treatment was monitored in UC cells using antibodies directed towards an N-terminal epitope 
in either protein only exposed in the conformational changed Bak or Bax. Primary antibody 
binding was visualized by a secondary FITC-conjugated antibody and the associated 
fluorescence signal monitored by flow cytometry. 
Characterisation of alterations in kinome signalling 
In Paper V melflufen-, melphalan-, or cisplatin induced effects on the kinome of UC cells was 
explored to reveal possible treatment combinations. The alterations in phosphorylation of about 
40 different growth factor receptor tyrosine kinases and their downstream kinases was studied. 
Profiling was commenced utilising PathScan® receptor tyrosine kinase signalling antibody 
array (Cell Signaling Technology, Danvers, MA, USA). In this assay biotinylated antibodies 
recognising the phosphorylated form of the individual proteins are applied followed by a 
streptavidin conjugate labelled with linked fluorescence. The resulting signal was recorded on 
the Odyssey Sa Infrared Imaging System (LI-COR). A positive and negative control included 
in the assay served to normalise signal intensity and to subtract background from each sample 
and each protein spot on the array. To verify phosphorylation of Src, an antibody targeting the 
phosphorylated form p-Src Y416 was used in western blotting of UC cells treated with 
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melflufen, dasatinib, and a combination thereof. The generated signal from the western blot 
was quantified on the Odyssey Sa Infrared Imaging System after correcting for loading 
differences using GAPDH.  
 
3.7 Statistical analyses  
The statistical calculations included parametric tests. In Paper II, III, IV, and V the survival 
models were compiled with the Kaplan-Meier method and the log-rank test (Breslow) was 
applied to compare two or more groups 155. The Cox proportional hazard model and the chi-
squared tests were implemented to compare parameters for prediction accuracy and categorical 
variables, respectively, in Paper II. Statistical significance was defined as p < 0.05. All 
statistical analyses were performed in SPSS© version 25 (IBM Corp, Armonk, NY, USA) and 
Excel 365© (Microsoft Corp, Redmond, WA, USA).   
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4 Results & Discussion 
4.1 Clinical Activity of Sorafenib in a Previously Treated Advanced Urothelial 
Cancer Patient (Paper I) 
In the mid noughties, the newly approved TKIs sorafenib and sunitinib, turned around the 
treatment strategy in renal cancer 95. For patients with adjacent tumours of the urinary tract, 
and with no other standardised treatment options, TKIs were an appealing avenue, nevertheless 
without being explored in UC until the end of that decade 156-158.  
In Paper I, tumour specimen was analysed from a UC patient with unexpected clinical benefit 
following treatment with sorafenib. This patient had a platinum-progressive, locally advanced 
UC with lung metastases and was without any remaining approved treatment options. 
Sorafenib was initiated off-label at a dose of 400 mg twice daily in line with approved dose for 
sorafenib in renal cell carcinoma. At the first treatment evaluation a decrease in the lung 
metastases were observed. The shrinkage of the pulmonary metastases continued until the 
evaluation at 8.7 months, but at the following examination, at 10.5 months, the metastases had 
progressed in size (Figure 3). Interestingly the lung metastases, not only initially, decreased in 
size in response to treatment, but also showed cavitation which may indicate a more necrotic 
than solid tumour state. The recorded PFS for this patient exceeded the longest and median 
PFS in the previously reported sorafenib Phase II trials, respectively 157,158. No studies have 
reported on sorafenib responses in metastatic UC patients, yet other TKIs including sunitinib 
and pazopanib have been shown to generate treatment benefit in selected cases 156,159. There is 
however no defined tumour genotype or phenotype that has been correlated to treatment benefit 
following these treatments. In the present study, IHC analyses of two suggested key targets for 
sorafenib, VEGFR2 and PDGFR-β were analysed in the patient’s tumour specimen and 
showed intermediate and high expression, respectively. For other diagnoses, including 
hepatocellular and renal cell carcinoma, it has been suggested that the expression of the 
expected targets for sorafenib, PDGFR-β and VEGFR2 may be correlated to treatment 
outcome, but this has never been clearly demonstrated 160. The patient described in Paper I 
tolerated sorafenib well but developed hypertension and skin reaction grade 2 (CTCAE 3.0) 
early on. The correlation of hypertension and rash during treatment with sorafenib and other 
TKIs, and favourable outcome, has been reported for other malignancies 161,162. 
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Figure 3. Computerised tomography scans demonstrating the radiological effects in response to 
treatment with sorafenib in a UC patient. CT images of the patient prior to treatment (left) and after 
1.6 months (right) showing size reduction of lung metastases.  
 
After 10.5 months the patient progressed on sorafenib treatment demonstrated by size increase 
in the lung metastases, which also again were more solid on the CT scans. Thereafter, the 
patient was offered further systemic treatment on-and-off with vinflunine for more than two 
years, in-between also receiving palliative radiotherapy.  
In summary, the results in Paper I together with previous Phase II trials indicate that subset of 
patients may have clinical benefit following treatment with sorafenib 157,158. Even though no 
radiological response was achieved in this patient, as defined by RECIST 1.1, it can be 
speculated if disease stabilisation demonstrated as size-reduction accompanied by changes in 
the composition of the metastases can translate into meaningful clinical benefit. Importantly, 
no firm conclusions can be drawn from case reports of individual patients, but the observations 
may still generate hypothesis which can be tested in subsequent prospective clinical trials. 
Following this pilot case and the subsequent approval of the vinca alkaloid vinflunine, attention 
was put on combining these two drugs as they have different mode of action and toxicity 
profiles 53,96,157. 
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4.2 Vascular endothelial growth factor receptor 2, but not S100A4 or S100A6, 
correlates with prolonged survival in advanced urothelial carcinoma (Paper II) 
One in two patients with muscle-invasive UC undergoing cystectomy or local resection will 
inevitably relapse, pointing towards a micro-metastatic disease already at this stage 119. In the 
clinical routine, the tools for predicting prognosis after the cystectomy is still, despite recent 
advances in tumour genome and proteome profiling, only based on anatomical and clincal 
features 14. If at hand, such a set of biomarkers in tumour tissue and/or plasma could potentially 
be used to guide further clinical management of the patient. Adding treatments upfront in a 
personalised way could thereby, further improve outcome. Multiple studies have focused on 
prognostic biomarkers for UC. These includes markers of proliferation: Ki67, cell cycle 
regulators: p53, and cell death associated proteins: Bcl-2 and caspase-3 163-166. Focus has also 
been on angiogenesis, e.g. microvessel density, VEGFA, and its receptor VEGFR2 167-170. With 
respect to VEGFR2, prior results are contradictory in terms of association between VEGFR2 
and clinical outcome 167,168,170. In Paper I, the prognostic potential of VEGFR2 protein 
expression in UC tumour specimen from patients undergoing cystectomy for a muscle-invasive 
UC was studied with the aim to reveal if VEGFR2 could be used as a biomarker for prognosis. 
In tumour specimens from a cohort of 83 UC patients, VEGFR2 expression was analysed by 
IHC. VEGFR2 expression was mainly found in the cytoplasm of tumour and endothelial cells 
as illustrated in Figure 4 (upper panel). The percentage of cells staining positive for VEGFR2 
were generally high in all patients’ specimen while the staining intensity varied from low to 
high.  
Based on VEGFR2 expression, patients were divided into high or low groups with a cut-off at 
moderate intensity and high score (≥75% of cells stained) (Figure 4, lower panel). 
Significantly longer OS (p = 0.014) was found in patients with high VEGFR2 tumour 
expression. An association between high VEGFR2 and outcome was also confirmed by 
applying Cox proportional hazards regression model, which further revealed that VEGFR2 
expression within UC tumour specimen was an independent variable associated with OS (p = 
0.046) and DFS (p = 0.04). These results are thus in line with findings of VEGFR2 expression 
in UC specimens retrieved by TURB from 114 patients and who observed increased OS in 
patients with >50% of UC cells expressing VEGFR2 167.  
In endothelial cells, VEGFR2 is known to be expressed on the cell surface and control 
endothelial proliferation, permeability, migration/invasion, and in the context of tumours 
enabling angiogenesis 171. In the present study, VEGFR2 expression was in most of the cases 
only in the cytoplasm of UC tumour cells. This result is to some extent puzzling, yet it has been 
shown that VEGFR2 may, as consequence of alternative splicing, generate a soluble form of 
VEGFR2 that can, when secreted, act as a suppressor of lymphatic vessel generation 172. One 
could speculate that the observed VEGFR2 expression in UC tumour specimen may in fact act 
as suppressor of lymphatic vessel formation and thereby influencing metastatic potential.  
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Figure 4. VEGFR2 expression in UC tumour specimen and association with overall survival. 
Immunohistochemistry (upper panel). Example of high VEGFR2 staining in UC specimen with high 
expression. Kaplan-Meier survival plot (lower panel). VEGFR2 expression was analysed in relation to 
OS probability dividing the cohort into low or high staining (by combined IHC score and intensity). 
Data presented from the publication with permission from the publisher.  
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In Paper II the prognostic value of the calcium-binding S100A proteins, S100A4 and S100A6, 
was also explored in the same UC patient cohort. The S100A proteins are known to control 
multiple hallmarks of tumours, including proliferation, differentiation, apoptosis and 
metastasis 173,174. In UC, S100A4 has been linked to metastasis and poor outcome 175-178. The 
analyses of S100A4 and S100A6 by IHC in Paper II of UC tumour specimen, revealed 
expression of both proteins in the cytosol of the specimen with some cases also showing nuclear 
localisation. Overall, the score (proportion of S100A4 and S100A6 positive cells) was high 
(median >75%), while signal intensity differed among the cases. Analysing a possible 
correlation between OS or DFS and S100A4 or S100A6 staining from the date of cystectomy 
did however not reveal any significant correlation (p > 0.05). Neither S100A4 nor S100A6 
showed an association to clinical outcome (measured from the date of cystectomy). The results 
in Paper II are in disparity with a large retrospective analysis on a bladder localised UC (n=315 
patients) which reported that S100A4 was significantly higher expressed in UC tumours of 
patients with lymph node or distant metastasis 179. The same study also identified S100A4 to 
be a prognostic marker for survival, with significantly shorter OS among patients with high 
S100A4 expression in UC cells. No studies have so far analysed S100A6 in UC specimen. 
However, in lung squamous cell carcinoma (n=177) a high S100A6 expression was correlated 
with lower OS 180. In sarcoma patients (n=50) a high expression of S100A6 was related with 
less disseminated disease 181. In pancreatic tumours a high nuclear staining of S100A6 was 
associated with shorter OS 182. S100A6 has also been evaluated as a serum biomarker for UC 
183. It was shown that higher serum levels of S100A6 in muscle invasive UC patients, relative 
to non-muscle invasive UC patients or healthy controls, indicating a putative role as a non-
invasive biomarker. 
In Paper II single biomarker expression by IHC has been explored, yet the path ahead is more 
likely global profiling of the genomic makeup of the individual tumour. The potential of such 
approaches is illustrated by both The Cancer Genome Atlas project (Cancer Genome Atlas 
research) and by studies of gene expression. Results from these studies have enabled sub group 
classification of UC thereby identifying signalling networks that could be targeted by small 
molecules with improved efficacy either alone or in combination with chemotherapy 184,185. 
With respect to VEGFR2 expression, further analyses in context of the identified UC subgroups 
are warranted as it could identify patients that would benefit more on VEGFR2 targeting 
therapies, possibly including sorafenib.  
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4.3 Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum 
Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial (Paper III) 
Paper III describes the result of the academic prospective Phase I trial Vinsor trial (EudraCT 
Number: 2011-004289-14, NCT01844947) in which the safety of the combined therapy of 
vinflunine plus sorafenib in previously platinum-treated metastatic UC patients was evaluated. 
The trial included 22 subjects between April, 2012, and September, 2017. The primary 
endpoint was to define the RPTD of the treatment combination of vinflunine plus sorafenib by 
evaluating safety parameters during treatment cycles 1 and 2. 
The MTD of vinflunine 280 mg/m2 day 1 and sorafenib on days 2-21 Q3W, was sorafenib 600 
mg (200 mg+ 400 mg). The DLTs presented in this cohort included febrile neutropenia (three 
patients, grade 3 (x2) and 4) and neutropenia (one patient, grade 4). All but one DLT in this 
cohort occurred at the highest dose level of sorafenib, 800 mg. Hence, for patients aged 75-80 
years, or PS 1, or previous radiotherapy to the lower pelvic region, or with reduced renal 
function (creatinine clearance 40-60 ml/min) but adequate hepatic function, the RPTD was 
vinflunine 280 mg/m2 day 1 and sorafenib 400 mg (200 + 200 mg) on days 2-21 Q3W. 
The MTD of vinflunine 320 mg/m2 day 1 and sorafenib on days 2-21 Q3W, could not be 
defined since three out of five patients had a DLT in the first dose cohort (sorafenib 400 mg). 
The observed DLTs were febrile neutropenia (two patients, grade 3 and 4) and hypertension 
(one patient, grade 3). Hence, for patients treated with vinflunine, 320 mg/m2 adding sorafenib, 
even at a dose of 400 mg daily, resulted in intolerable toxicity.  
Only two of the seven DLTs recorded resulted in permanent study treatment withdrawal: one 
patient had a DLT at cycle 1 day 3 (hypertension, grade 3) and one patient at cycle 1 day 7 
(neutropenia, grade 4). In total, five patients discontinued treatment during cycle 1.  
The most frequently reported side-effect was fatigue (16 patients/80%); including two grade 3. 
The second overall most frequent toxicity was constipation (13 patients/60%); however, none 
above grade 2. The most frequently observed grade ≥3 toxicities were neutropenia (six 
patients), febrile neutropenia (five patients), and hyponatremia (five patients). No grade 5 side-
effects were recorded. Clinical side effects including hypertension and rash have been 
suggested to be correlated to treatment benefit in response to TKIs, by others as well as in 
Paper I but these adverse events were not more frequent in subjects responding to therapy in 
the present study 186,187.  
The secondary endpoints were survival and response outcome. The ORR among the patients 
for whom efficacy could be evaluated was 41% (7 of 17 patients), all being partial responses 
by RECIST 1.1. Disease control rate (DCR) was 71% (12 of 17 patients). The measured 
changes in target tumour lesions over time are presented in Figure 5.  
Median study treatment was 4.1 months (0.1-14.5) among the DLT evaluable patients. 
Including all patients, the median OS was 7.0 months (1.8-41.7) and PFS was 4.5 months (1.2-
16.1). The validated baseline prognostic factors for second-line treatment: PS, liver metastasis, 
and anaemia, were analysed for impact on survival outcome 131. No statistically significant 
divergence in OS or PFS based on number of prognostic factors at baseline was found among 
the patients in this trial.  
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Figure 5. Visualisation of tumour response in the Vinsor study. The presented spider plot shows 
measured changes in target tumour lesions over time. Most of the treated patients within the Vinsor 
study had a size reduction of the target lesions in response to treatment; 41% of the patients fulfilled 
RECIST 1.1 for being partial responders. Colour codes: PR (partial regression), SD (stable disease), PD 
(progressive disease). 
 
In the present study sorafenib was selected to be combined with vinflunine based on different 
action mechanisms, namely inhibition of angiogenesis and microtubule formation, 
respectively. The combination of sorafenib with vinflunine was also applied based on the 
potentially compatible toxicity profiles of the two drugs and the reports of individual patients 
responding to sorafenib (100; Paper I). The outcome of the Vinsor trial, in which a RPTD was 
defined with vinflunine 280 mg/m2 and sorafenib 400 mg, provides a safe foundation for further 
clinical evaluation in metastatic UC patients. 
Several previous trials of vinflunine doublets, including pazopanib, pemetrexed, and erlotinib 
have all terminated prematurely because of unacceptable toxicity (mainly neutropenia, 
thrombocytopenia, and fatigue) 55,57,188. Only one study has reported acceptable toxicity with 
combined vinflunine per os and TKI; erlotinib with oral administration of vinflunine in second-
line or beyond therapy of lung cancer 189. Sorafenib has however been evaluated in combination 
with chemotherapies including gemcitabine and paclitaxel in platinum-resistant UC patients in 
which a single response (partial) in twenty treated patients was evident 190.  
The ORR of 41% observed in the present Vinsor trial compares favourably with the ORR of 
8.6%-18% in the efficacy evaluating Phase II and III studies of vinflunine in metastatic UC 51-
53. Neither of two reported Phase II trials on sorafenib monotherapy in metastatic UC (n=27 
and n=20) demonstrated any treatment responses 157,158. Though, the confirmed treatment 
responses in the present study did not translate into longer OS or PFS. This outcome is similar 
with previous vinflunine trials 53,157,158. It can however be discussed whether a tumour response 
still may generate a clinically meaningful palliative benefit for the responding patients. 
In summary, Paper III reports a RPTD for the treatment combination of sorafenib plus 
vinflunine in UC patients with early post-platinum progressive generalised disease. An additive 
anti-tumoral effect for this combination is plausible although the number of treated patients in 
the present study was too small to draw a definite conclusion on efficacy. Future randomised 
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studies are needed to evaluate vinflunine and sorafenib in this setting alongside with 
approaches to identify biomarkers for treatment benefit.  
 
4.4 Early Evaluation of Vinflunine and Sorafenib Treatment Responses in Metastatic 
Urothelial Cancer Patients by Use of Explorative 18F-FDG PET CT and Plasma 
Exosome Analyses (Paper IV) 
Early treatment evaluation approaches which can separate patients that benefit from the given 
treatment from non-responders, remains an unmet medical need for patients with late-stage, 
metastatic UC. In Paper IV the putative predictive value of early response assessment of 
combined vinflunine plus sorafenib treatment by use of early 18F-FDG-PET CT scans and 
longitudinal plasma exosome analyses (Figure 2). From the Vinsor trial (Paper III) thirteen 
patients that had consented to participate were included. These patients were analysed with 18F-
FDG-PET CT scans at baseline and prior to initiate treatment cycle two (= three weeks later). 
The metastatic lesions observed in these patients reflected the typical pattern of metastasis seen 
in patients with advanced UC with distribution to lymph nodes, visceral organs including lungs, 
adrenal glands and bone. Patients were dichotomised into partial responders and non-
responders based on changes in maximal 18F-FDG PET calculated SUVmax and SUVpeak in 
tumour lesions in comparison to the baseline examination in which various thresholds were 
tested. Patients with a SUVmax and SUVpeak decline of ≥10% after one cycle of treatment had a 
significant longer OS than patients with <10% SUVmax or SUVpeak reduction at the same time 
point (p = 0.039). Metabolic response on 18F-FDG PET at 3 weeks, by use of this adapted 
threshold, could predict best response by RECIST 1.1 in 11 out of 13 patients as seen in Figure 
6.  
 
Figure 6. Explorative early treatment evaluation by use of 18F-FDG-PET CT after one treatment 
cycle of combined sorafenib and vinflunine treatment in UC patients. Relative changes in delta 
SUVpeak in comparison to the baseline values are shown for each patient. The corresponding best 
response as assessed by conventional CT and RECIST 1.1 is shown with the following colour codes: 
partial regression (green), stable disease (blue), progressive disease (red).  
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On the contrary, and for unclear reasons, there was no significant correlation between 
metabolic response and PFS was observed. It is reasonable to anticipate a time-dependent 
dynamic process of tumour metabolic activity and response, why early evaluations may need 
modified thresholds for defining treatment response. By use of a similar approach, with the aim 
of optimising the threshold for defining response and OS, a 10 % reduction of the sum of long 
axis diameter evaluated by CT, was found to be superior to standard RECIST criteria in UC 
patients treated with vinflunine in monotherapy 191. The potential value of early 18F-FDG 
PET/CT assessment during treatment with TKIs and chemotherapy has been demonstrated in 
other cancer diagnoses including renal and colorectal 192,193. If other PET tracers, such as 11C-
choline and 18F-FLT can further improve this early treatment evaluation approach for patients 
with metastatic UC, remains unclear but should be explored. Similarly, the optimal timing for 
the early 18F-FDG-PET CT evaluation during the treatment course needs to be addressed in 
future studies.  
Further, in Paper IV, isolated EVs (at baseline, day 8 and day 21) from plasma samples of five 
UC patients in the Vinsor trial (Paper III) with short or long survival were analysed (Figure 
2). NTA demonstrated that all plasma samples from the UC patients analysed contained EVs 
with sizes 100-120 nm, in line with earlier reported exosome sizes in other tumour types 
138,194,195. One analysed patient had EVs of a larger size (200-350 nm). Western blot analyses 
of these samples confirmed the expression of at least one of the exosome markers CD9 and 
CD63, yet with no consistent variation seen during the treatment course. To reveal if 
differences in concentration of exosome-sized EVs in plasma could be linked to treatment 
outcome, NTA was used to quantify the number of EVs in a defined volume of plasma. Results 
showed that the level of EVs at baseline differed between the analysed subjects, ranging from 
~2x109 to ~2x1010. There was also a clear alteration in amount of EVs during the treatment 
course, and at day 8 four out of five patients showed increased level of plasma EVs which was 
not linked to treatment outcome (Figure 7).  
As the exosome isolation method did not separate tumour specific exosomes from exosomes 
generated from other cells it may well be so that exosomes from infiltrating immune cells 
and/or other normal cells also contributed to the observed alterations. Further analyses should 
use tumour and/or immune specific surface markers to sort out subsets of exosomes on which 
global miRNA or protein profiling could be applied to reveal individualised biomarkers for 
treatment monitoring. Global miRNA profiling of exosome from UC patients has already been 
demonstrated to be feasible and a biomarker subset linked to non-invasive UC and metastatic 
UC have been reported 137,196. Thus, focusing on these miRNAs in the context of treatment with 
combined vinflunine and sorafenib could be one way forward. Interestingly, for one of the 
biomarkers analysed in Paper II, S100A4, it has been demonstrated that exosomes isolated 
from UC cells in vitro and urine from C patients express this protein. Besides, adding such 
exosomes to UC cells promoted their epithelial to mesenchymal transition process 197. Another 
path forward could therefore be to profile for S100A4 and associated EMT signalling of the 
plasma derived exosomes from UC patient plasma in the Vinsor trial 198. 
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Figure 7. Analysis of EVs from patients with metastatic UC treated within the Vinsor trial. Plasma 
samples were taken from UC patients with short (109, 113) or long (107, 111, 114) treatment response 
and EVs were isolated by size exclusion chromatography. Isolated EVs were analysed with respect to 
counts per ml plasma at baseline (day 0), and during treatment (day 8, day 21). Results are shown in 
relation to OS of each patients.  
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4.5 Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy 
and the Src inhibitor dasatinib in urothelial carcinoma (Paper V) 
In Paper V the aim was to analyse if the peptidase enhanced alkylating agent melflufen which 
has demonstrated efficacy in solid tumours and haematological malignant cells (see section 
1.5.2) could be a putative chemotherapy for UC. For that purpose, the effect of melflufen on 
UC cell lines in vitro was examined. The results of Paper V are summarised in Figure 8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Melflufen-induced signalling in UC cells in vitro. Melflufen treatment of UC cells results 
in intracellular accumulation of intact melflufen which either may be deesterified by esterases cleaved 
by aminopeptidases in cytosol to generate melphalan (I). Inhibition of aminopeptidases by bestatin 
reduces melphalan accumulation and partially blocks melflufen-induced cell death. Melphalan may in 
theory encounter ANPEP expressed on the cell surface (I). Free melphalan alkylates the DNA resulting 
in DNA damage (II). The subsequent DNA damages trigger activation of Bak/Bax, release of 
cytochrome c and subsequent caspase-9/3 activation and apoptotic morphology (IIIa). Signals from the 
melphalan-induced DNA damage may block growth factor receptor-regulated kinases and proliferative 
signalling (IIIb). Phosphorylated Src still remains after melflufen-treatment of UC cells and promotes 
cell survival. Treatment with dasatinib combined with melflufen blocks Src phosphorylation and 
increases cell death signalling. 
 
Profiling of melflufen cytotoxicity and induction of apoptosis in UC cells revealed higher 
degree of cell death compared to melphalan. Thus, melflufen activated pro-apoptotic Bcl-2 
proteins Bak and Bax, followed by cleavage of pro-caspase-9/PARP-1 resulting in apoptotic 
nuclear morphology.  
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Combined treatment of melflufen and cisplatin or gemcitabine demonstrated additive cytotoxic 
effects with increased cell death in line with published data on other tumour types64,67. For 
gemcitabine and cisplatin, the additive effect when combined with melflufen may directly be 
attributed to inhibition of DNA repair processes required for repair of melphalan-inflicted DNA 
damages, e.g. inhibition of DNA polymerase by gemcitabine, or alteration of cell cycle 
distribution by cisplatin 199-201. The additive effect could also be a result of blockade of growth 
factor survival kinases of either agent, tilting the UC cells towards apoptosis. 
To further understand possible effects of melflufen on the UC cell signalome as well as to 
reveal novel treatment combinations PathScan RTK signalling antibody array was applied. 
Multiple growth factor receptors previously linked to UC and/or sorafenib response, e.g. 
PDGFR, FGFR3 and c-Kit, showed reduced phosphorylation after melflufen treatment 26,198. 
In line with previous results from cisplatin-treated UC cells, phosphorylation of Src remained 
high after melflufen treatment 202. By adding dasatinib, a Src-family kinase inhibitor, a 
reduction in Src phosphorylation was evident and when combined with melflufen a significant 
increased cell death seen. Interestingly, a Phase I clinical trial of dasatinib in a neoadjuvant 
setting of UC and prior to cystectomy, was successfully conducted and the primary endpoint 
(feasibility) reached 78. Albeit the metastatic UC tumour specimen in that study showed 
reduced phosphorylation of Src after dasatinib exposure, this monotherapy did not reduce 
tumour cell proliferation or induced apoptosis. Nevertheless, it illustrates that Src may be a 
target that could be further explored in mUC for chemotherapy sensitisation.  
Melflufen results in melphalan loading in tumour cells of different origin and that is partly 
controlled by bestatin-blocked aminopeptidases due to peptidase activating in the tumour 
58,62,64,73. In Paper V it was similarly demonstrated that exposure of UC cells to melflufen 
results in a time dependent increase of melphalan. Importantly, comparing melflufen with 
melphalan revealed a ~20-fold higher accumulation of melphalan after adding melflufen to UC 
cells, illustrating that the concept of peptidase enhancement also works in UC cells 58,64,73. 
There was also some intact melflufen as well as a deesterified form observed in UC cells which 
decreased over time accompanied by increased level of melphalan, suggesting that there are 
maybe peptidases with different efficiency or kinetics which act on melflufen in UC cells. To 
verify that aminopeptidases were involved in the biotransformation of melflufen to melphalan 
in UC cells, bestatin, an inhibitor of multiple aminopeptidases was applied. A partial reduction 
(~40%) of melphalan accumulation after melflufen exposure was found and a 50% inhibition 
of melflufen-induced cytotoxicity was recorded. These results demonstrate that 
aminopeptidases are involved in the biotransformation of melphalan from melflufen in UC 
cells. In other cell systems, a critical role for ANPEP has been observed. 58,64,73. It remains 
however to be elucidated, which aminopeptidases that are operative on melflufen in UC cells. 
Interestingly, a recent report showed that bestatin (Ubenimex), an inhibitor of ANPEP and 
likely of other aminopeptidases, may per se inhibit UC cell viability and migration/invasion 
capacity illustrating that targeting ANPEP may also be therapeutic way for UC 203.  
ANPEP shows deregulation in tumours and may be used for imaging or therapy purposes (see 
section 1.5.2). ANPEP expression was therefore analysed in tumour specimen (n=83) from the 
same UC patient cohort used in Paper II. Results showed that all, but one case, were positive 
for ANPEP and had a higher expression in tumour relative to non-tumour tissue. ANPEP was 
mainly localised to the tumour cells per se and not to the stroma as previously been shown in 
other studies 74,75. Both ANPEP staining intensity, as well as the %-positive cells varied 
between the UC specimen with most of the cases (n=77) having 76-100% positive cells. The 
staining was both cytosolic and membranous in 20 cases, only cytosolic in 60 cases while two 
cases showed only membranous staining. ANPEP expression was subsequently analysed in 
relation to survival of the patients by dividing the cohort into high ANPEP (histoscore ˃5) or 
low ANPEP (histoscore˂ 5) expression. It was demonstrated that patients with high ANPEP 
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expression had a longer OS (p = 0.02; median OS 8.1 years vs 3.2 years; mean OS 7.9 years vs 
5.7 years) while no difference in DFS was found. ANPEP has in some tumour types been linked 
to poor prognosis but in others not been linked to outcome at all 70,73,75. In Paper V it is 
demonstrated that high ANPEP expression may be correlated to favourable OS, which also has 
been shown in gastric carcinoma and prostate cancer 204 205. Given the recent subgroup 
classification of UC tumours by genomic methods it would be appealing to test if ANPEP 
expression is linked to a certain subclass of UC, as it may for the future guide therapies 184,185. 
In summary, Paper V shows that melflufen may be a novel therapy for UC either alone but 
more likely combined with conventional chemotherapy or Src blockade. Guiding of ANPEP 
in UC specimen suggest ANPEP to be a putative biomarker for directing melflufen-based 
therapies in UC.  
 
 
 
 
 
 

  31 
5 Conclusions 
In Paper I the presented clinical data indicated that a benefit may be achieved with sorafenib 
in metastatic UC even though no definitive response as defined by RECIST was observed. IHC 
expression profiling of key targets for sorafenib, VEGFR2 and PDGFR-β, may be of relevance 
for treatment gain but prospective and properly sized biomarker-driven clinical trials are 
needed to verify this observation in the context of other possible biomarkers.  
In Paper II, low VEGFR2 expression was associated with the risk of disease relapse and 
shorter survival in UC patients, treated by cystectomy. Hence, if the prognostic property of 
VEGFR2 can be verified, this protein may hold potential as a biomarker. Pre-cystectomy 
S100A6 expression differed among patients surviving beyond 18 months, suggesting that this 
protein may intervene in the development of micro-metastasis. Further studies are warranted 
of VEGFR2 including re-evaluation of S100A4 and S100A6 to confirm their prognostic value 
to UC patients.  
In Paper III the Phase I trial Vinsor determined the RPTD for the treatment combination of 
vinflunine plus sorafenib in patients (n = 22) with post-platinum progressive disease; vinflunine 
280 mg/m2 day 1 and sorafenib 400 mg (200 + 200 mg) on days 2-21 Q3W. Combining 
vinflunine 320 mg/m2 with sorafenib was too toxic. Side-effects were manageable and 
expected but with higher incidence of hyponatremia than previously reported. The ORR to this 
treatment combination was 41% and the median OS was 7.0 months.  
In Paper IV it was demonstrated that patients on combined treatment with vinflunine and 
sorafenib, can be evaluated for early treatment response by use of 18F-FDG-PET. Here a 
modified response-threshold of PERCIST (≥10% SUVmax or SUVpeak reduction) could predict 
treatment response and was correlated to OS. Plasma derived exosomes with intrapatient 
differences in absolute numbers during treatment were found, but with no clear correlation to 
outcome in a subset of patients.  
In Paper V the peptidase-activated alkylating agent melflufen was for the first time reported 
to induce cytotoxicity in UC cell lines. It was demonstrated that melflufen could be combined 
with standard chemotherapy but also that a blockade of Src offers an alternative combination 
regimen. The pharmacodynamic profiling of melflufen revealed a higher concentration of 
melphalan in UC cells, involving activity of aminopeptidases. One of these peptidases, ANPEP 
was characterised in UC clinical specimens and expression was associated with improved 
clinical outcome.  
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6 Future perspectives 
Advanced and metastatic UC was the focus of this thesis. Management of this disease in the 
palliative setting requires careful consideration of the best treatment strategy for each patient 
14. Up till now, the optimal therapy decisions have been based on general evidence, with few 
clinical and no genetic or phenotype parameters in the decision models 206. The purpose of this 
thesis was to address these shortcomings by exploring potential prognostic and predictive 
biomarkers along with novel treatments and imaging technology. 
As more treatment options emerge in late stage UC, prognostic and predictive biomarkers for 
treatment response will, for certain, have an increased impact on the selection of therapy. 
Learning from the collected data in The Cancer Genome Atlas, attention is focusing on 
delivering precise and tailored drug candidates in UC 207. Examples are emerging of trials in 
advanced UC prospectively analysing the predictive value of biomarkers, e.g. PDL1 and 
tumour mutation burden in the neoadjuvant setting with pembrolizumab 38. Prospective trials 
in metastatic UC may include platform studies, as new drug classes with different 
pharmacodynamic principles are added to chemotherapy. 
Following the results of the Phase I trial Vinsor (Paper III), the next reasonable goal is to set 
up a randomised study to evaluate the additive efficacy value of sorafenib to standard second-
line chemotherapy. Clinical research on developing chemotherapy regimens with targeted 
therapy along with immunotherapies will remain a key area for identifying future regimens in 
second-line and beyond. Monotherapy with PD1/PDL1 inhibitors have reported response rates 
of up to 24% in second-line, which is impressive but leaves room for improvement in overall 
response outcome 208. In a recently reported Phase I/II study in metastatic UC patients treated 
with combined PD1 and CTLA-4 inhibitors, subgroup stratification based on PDL1 expression 
found a response rate of 58% in patients with high PDL1 expressing UC tumours 209. Worth 
noting are the recently enforced limitations to the treatment indications sanctioned by EMA for 
atezolizumab and pembrolizumab. These drugs are presently only approved in UC patients 
unfit for cisplatin-based therapy with PDL1 score ≥5% or PDL1 combined positive score ≥10, 
respectively 83,85. This decision to curb the indications of immunotherapies reinstitutes 
chemotherapies, most notably carboplatin, as the drug of choice for treatment combinations. 
This will keep the field open to more interesting combinations with chemotherapy and targeted 
drugs for the foreseeable future.  
The availability of precise and high-definition functional imaging is fundamental to 
understand, evaluate, and develop new treatments in cancer 210,211. Reports of molecular 
imaging with reactive probes, including ANPEP, are generating promising results with detailed 
specificity in pre-clinical models 70. This technology should be expanded into clinical research 
on UC patients with the aim to select optimal treatment on a tumour individual basis.  
The results from Paper V showing efficacy of the aminopeptidase activated alkylating agent 
melflufen in UC cells in vitro highlights the priority to setup an early stage trial in metastatic 
UC. The recent achievements in late-stage myeloma of melflufen versus standard-of care 
pomalidomide, which significantly increased response and prolonged survival in a Phase II 
trial further supports pharmacodynamic properties of melflufen 62.  
During the last decade advances in bioinformatics and nanotechnology have contributed to the 
knowledge and research possibilities in UC. As this momentum in medical research is 
increasing, new tools to diagnose, profile, and ultimately tailor treatment will influence future 
treatment decisions in complex diseases, such as cancer, and especially in cancers with high 
mutational burden 212. Exosomes as biomarkers and diagnostic tools is one example of an 
emerging application under development to possibly dynamically monitor and describe 
treatment response in UC 213,214. 
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Finally, as an acknowledgement of the intense research focusing on UC, there are over one 
hundred registered clinical studies worldwide trying to identify new treatments, indications or 
combinations in metastatic UC 207. A future prospective trial in metastatic UC patients may 
advantageously implement an adaptive randomisation in the study design. This trial strategy 
would more rapidly provide the newly obtained predictive information applicable to other 
study subjects. Developing new treatments and improved evaluation methods in metastatic UC 
are top priorities to increase survival outcome.  
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